Drug Type Small molecule drug |
Synonyms pro-apoptotic mitochondrial respiration disrupters(Sanford-Burnham), SMIP-004, SMIP-004-7 + [1] |
Target |
Action agonists, inhibitors |
Mechanism ROS1 agonists(Proto-oncogene tyrosine-protein kinase ROS agonists), SKP2 inhibitors(S-phase kinase associated protein 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC13H19NO |
InChIKeyZFVMECVBUGMWIX-UHFFFAOYSA-N |
CAS Registry143360-00-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Ductal Adenocarcinoma | Preclinical | China | 10 Apr 2024 | |
Castration-Resistant Prostatic Cancer | Preclinical | Canada | 01 Aug 2015 | |
Prostatic Cancer | Discovery | United States | - |